ROBERT M. NALBANDIAN, M.D.
To the editor: In their paper (1), Lipp, Rudders, and Pisciotta reported the failure of urea therapy in the oral, prophylactic mode in five sickle-cell patients treated from 3½ to 7 weeks. Statistically significant increases in blood urea nitrogen (BUN) levels are cited, even though they indicate the specified BUN levels of 40 to 60 mg/100 ml (or higher), as required in our published protocols (2-4), were never achieved. Furthermore, the dosage schedule for urea therapy was significantly below that specified in our protocols. The beneficial effects of urea therapy in sickle-cell disease depend on achieving and maintaining adequate BUN
Learn more about subscription options.
Register Now for a free account.
NALBANDIAN RM. Oral Urea in Sickle-Cell Disease. Ann Intern Med. 1972;77:659–660. doi: 10.7326/0003-4819-77-4-659_2
Download citation file:
Published: Ann Intern Med. 1972;77(4):659-660.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only